Taysha Gene Therapies Files Q1 2025 10-Q
Ticker: TSHA · Form: 10-Q · Filed: May 15, 2025 · CIK: 1806310
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
Taysha Gene Therapies filed its Q1 2025 10-Q, showing financial updates and key events.
AI Summary
Taysha Gene Therapies, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31. Key dates mentioned include April 30, 2025, for subsequent events and June 26, 2024, related to underwriting agreements for pre-funded warrants.
Why It Matters
This filing provides investors with an update on Taysha Gene Therapies' financial performance and material events during the first quarter of 2025.
Risk Assessment
Risk Level: medium — The company operates in the biotechnology sector, which is inherently high-risk due to research and development uncertainties and regulatory hurdles.
Key Numbers
- 20250331 — Period End Date (The financial information in this report pertains to this date.)
- 20250515 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — Period of report
- 20250515 (date) — Filing date
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX 75247 (address) — Business and mailing address
- June Twenty Twenty Four Pre-Funded Warrants (financial_instrument) — Mentioned in relation to underwriting agreements
FAQ
What is the primary business of Taysha Gene Therapies, Inc.?
Taysha Gene Therapies, Inc. is involved in Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When is Taysha Gene Therapies' fiscal year end?
Taysha Gene Therapies' fiscal year ends on December 31.
What is the SEC file number for Taysha Gene Therapies?
The SEC file number for Taysha Gene Therapies is 001-39536.
What subsequent event is noted with a date of April 30, 2025?
The filing notes a 'SubsequentEventMember' with the date 2025-04-30.
What specific type of warrants were part of an underwriting agreement on June 26, 2024?
The underwriting agreement on June 26, 2024, involved 'June Twenty Twenty Four Pre-Funded Warrants' and 'June Twenty Twenty Four Pre-Funded Warrants Option One'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Taysha Gene Therapies, Inc. (TSHA).